Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Gilead Sciences
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 4 ans
A study with four oral anti-Hepatitis drugs in patients with Hepatitis C who have already had at least one round of treatment
• To evaluate the antiviral efficacy as measured by SVR of combination therapy with GS-5885, GS-9451, tegobuvir and RBV compared with GS-5885, GS-9451 and tegobuvir or GS-5885, GS-9451 and RBV in trea...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences Limited
MAJ Il y a 4 ans
A Phase IV, Open-label, Prospective Observational Study to Evaluate Virological Response in Antiretroviral-Experienced HIV-1 infected Subjects Switching to Atripla (efavirenz/emtricitabine/tenofovir DF) on an Empty Stomach
To evaluate pure virological response rates (defined as subjects who do not have pure virologic failure at HIV-1 RNA threshold of 50 copies/mL) in antiretroviral-experienced subjects receiving Atripla...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 4 ans
A study to investigate the dose, safety and effectiveness of an experimental drug called elvitegravir for the treatment of HIV infection in children and adolescent patients. Patients must have previously received treatment for their HIV infection, and elvitegravir will be added to their current treatment which must include a ritonavir-boosted protease inhibitor
The primary objectives of this study are: •To evaluate the steady-state PK and confirm the dose of EVG/r in HIV-1 infected, antiretroviral treatment-experienced subjects 4 weeks to less than 18 ye...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 4 ans
An investigational study to assess the safety and effectiveness of a new investgational drug in people with moderately to severely active Ulcerative Colitis
• To evaluate the efficacy of GS-5745 to induce EBS clinical remission at Week 8 (Cohort 1) • To evaluate the efficacy of GS-5745 to maintain EBS clinical remission at Week 52 (Cohort 2) • To evalua...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences Incorporated
MAJ Il y a 4 ans
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF)
The primary objective of the study is to determine if ambrisentan is effective in delaying disease progression and death in subjects with IPF.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 4 ans
A Long Term Study to Follow the Safety of a New Treatment in Patients with Ulcerative Colitis
To observe the long-term safety of filgotinib in subjects who have completed or met protocol specified efficacy discontinuation criteria in a prior Gilead-sponsored filgotinib treatment study in UC
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 4 ans
A trial looking at the treatment of SOF/GS-5816 for 12 weeks against the treatment of Sofosbuvir and Ribavirin for 24 weeks in patients with hepatitis C infection
The primary objectives of this study are: * To compare the efficacy of treatment with sofosbuvir (SOF)/GS-5816 fixed dose combination (FDC) for 12 weeks with that of SOF + ribavirin (RBV) for 24 ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, S.L
MAJ Il y a 4 ans
Phase IV, multicenter, randomized, open-label pilot study of Truvada or Emtricitabine alone versus HAART interruption in HIV-infected patients who need to interrupt HAART and who are infected with HIV isolates containing at least 2 TAMs (or K65R) and M184V (GMB Study). Estudio piloto, multicéntrico y aleatorizadode fase IV, de Truvada o emtricitabina solos frente a la suspensión del TARGA en pacientes infectados por el VIH-1 que deciden interrumpir el TARGA y que están infectados por cepas del VIH-1 que contienen como mínimo 2 TAM (o K65R) y M184V (estudio GMB)
To compare the immunologic changes with different treatment approaches after HAART discontinuation.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Gilead Sciences, Inc
MAJ Il y a 4 ans
A Phase 2, Randomized, Open-Label trial of GS-9256 plus GS-9190 alone and in combination with Ribavirin for 28 days in Treatment Naive Subjects with Chronic Genotype 1 Hepatitis C Virus Infection
The primary objectives of this study are as follows: • To describe the antiviral efficacy of GS 9256 plus GS 9190 alone and in combination with ribavirin (RIBA) against genotype 1 hepatitis C virus (...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme
Entre 18 ans
et 99 ans
Gilead Sciences
MAJ Il y a 4 ans
Etude GS-US-313-1580 : étude de phase 3 randomisée, multicentrique comparant la tolérance et l’efficacité de l’administration chronique de 2 doses d’idélalisib chez des patients adultes ayant un lymphome folliculaire (LF). [essai clos aux inclusions]
Le lymphome folliculaire est le 2ème type le plus courant de lymphome non hodgkinien (LNH). Il existe de différentes options de traitement pour le lymphome folliculaire. Cependant ce type de LNH réap...
Pays
France
Organes
Lymphomes non hodgkinien
Spécialités
Thérapies Ciblées
Essai clos aux inclusions
Plus d'informations
Précédent
8
9
10
11
12
13
14
15
16
17
Suivant